Pfizer Exec Says Shares Bristol Myers' View That Co Has The Ability To Navigate The Impact Of IRA On Eliquis; Eliquis Will Be An Important Drug In Co's Portfolio For The Foreseeable Future, From A Net Present Value Perspective, The Impact Of Ira On...
Pfizer Exec Says Shares Bristol Myers' View That Co Has The Ability To Navigate The Impact Of IRA On Eliquis; Eliquis Will Be An Important Drug In Co's Portfolio For The Foreseeable Future, From A Net Present Value Perspective, The Impact Of Ira On...
辉瑞公司高管表示，与百时美施贵宝公司的看法相同，该公司有能力应对IRA对艾力昔单抗的影响；艾力昔单抗从净现值的角度来看，在公司组合中将是一种重要的药物，并将在可预见的未来继续使用。
Pfizer Exec Says Shares Bristol Myers' View That Co Has The Ability To Navigate The Impact Of IRA On Eliquis; Eliquis Will Be An Important Drug In Co's Portfolio For The Foreseeable Future, From A Net Present Value Perspective, The Impact Of Ira On Pfizer Is Somewhat Muted; Says $1.5B Of Cost Savings Is Only From Phase One Of A Multiple Phase Program
辉瑞高管表示与Bristol Myers一样，公司有能力应对IRA对艾克替尼的影响。艾克替尼将在未来可见的时间内成为公司组合中重要的药品。从净现值的角度看，IRA对辉瑞的影响有所减轻。他表示，15亿美元的成本节约仅来自多阶段计划的第一阶段。
- Conf Call
- 电话会议